BACKGROUND: We examined the effect of hepatitis C virus (HCV) seropositivity on risk of death among people receiving their first antiretroviral treatment (ART) for HIV infection. METHODS: In British Columbia, the HIV/ AIDS Drug Treatment Program is the only source of free ART. Patients who initiated a triple-drug ART regimen between July 31, 1996, and July 31, 2000, were included if they were ART-naive and had baseline HCV serological data. Outcomes of interest for survival analysis were deaths from natural and HIV-related causes, with a data cutoff of June 30, 2003. RESULTS: Of 1186 eligible subjects, 606 (51%) were HCV positive and 580, negative. Fewer HCV-positive people were male (78% v. 93%, p < 0.001) and had an AIDS diagnosis at baseline (11% v. 15%, p = 0.028). Their CD4 fraction was significantly higher at baseline (19% v. 16% of T lymphocytes, p < 0.001) but their absolute CD4 counts, log HIV viral load and the type of ART initiated were similar to those of HCV negative people. Of 163 deaths (from natural causes only) during the study period, 118 (19%) were in HCV positive and 45 (8%) in HCV negative patients (p < 0.001); of the 114 deaths attributed to HIV infection, these proportions were 79 (13%) versus 35 (6%; p < 0.001). After adjustment for potential confounders, HCV seropositivity remained predictive of death (adjusted hazard ratio [HR] 2.20, 95% confidence interval [CI] 1.50- 3.21, p < 0.001), especially HIV-related death (adjusted HR 1.75, 95% CI 1.13- 2.72, p = 0.012). INTERPRETATION: In this population-based HIV treatment program, we found HCV seropositivity to be an independent predictor of mortality, especially death related to HIV infection.
BACKGROUND: We examined the effect of hepatitis C virus (HCV) seropositivity on risk of death among people receiving their first antiretroviral treatment (ART) for HIV infection. METHODS: In British Columbia, the HIV/ AIDS Drug Treatment Program is the only source of free ART. Patients who initiated a triple-drug ART regimen between July 31, 1996, and July 31, 2000, were included if they were ART-naive and had baseline HCV serological data. Outcomes of interest for survival analysis were deaths from natural and HIV-related causes, with a data cutoff of June 30, 2003. RESULTS: Of 1186 eligible subjects, 606 (51%) were HCV positive and 580, negative. Fewer HCV-positive people were male (78% v. 93%, p < 0.001) and had an AIDS diagnosis at baseline (11% v. 15%, p = 0.028). Their CD4 fraction was significantly higher at baseline (19% v. 16% of T lymphocytes, p < 0.001) but their absolute CD4 counts, log HIV viral load and the type of ART initiated were similar to those of HCV negative people. Of 163 deaths (from natural causes only) during the study period, 118 (19%) were in HCV positive and 45 (8%) in HCV negative patients (p < 0.001); of the 114 deaths attributed to HIV infection, these proportions were 79 (13%) versus 35 (6%; p < 0.001). After adjustment for potential confounders, HCV seropositivity remained predictive of death (adjusted hazard ratio [HR] 2.20, 95% confidence interval [CI] 1.50- 3.21, p < 0.001), especially HIV-related death (adjusted HR 1.75, 95% CI 1.13- 2.72, p = 0.012). INTERPRETATION: In this population-based HIV treatment program, we found HCV seropositivity to be an independent predictor of mortality, especially death related to HIV infection.
Authors: D M Patrick; M W Tyndall; P G Cornelisse; K Li; C H Sherlock; M L Rekart; S A Strathdee; S L Currie; M T Schechter; M V O'Shaughnessy Journal: CMAJ Date: 2001-10-02 Impact factor: 8.262
Authors: G Greub; B Ledergerber; M Battegay; P Grob; L Perrin; H Furrer; P Burgisser; P Erb; K Boggian; J C Piffaretti; B Hirschel; P Janin; P Francioli; M Flepp; A Telenti Journal: Lancet Date: 2000-11-25 Impact factor: 79.321
Authors: Robert S Hogg; Katherine Heath; David Bangsberg; Benita Yip; Natasha Press; Michael V O'Shaughnessy; Julio S G Montaner Journal: AIDS Date: 2002-05-03 Impact factor: 4.177
Authors: E S Daar; H Lynn; S Donfield; E Gomperts; S J O'Brien; M W Hilgartner; W K Hoots; D Chernoff; S Arkin; W Y Wong; C A Winkler Journal: J Infect Dis Date: 2001-01-12 Impact factor: 5.226
Authors: Patrick G Yeni; Scott M Hammer; Charles C J Carpenter; David A Cooper; Margaret A Fischl; Jose M Gatell; Brian G Gazzard; Martin S Hirsch; Donna M Jacobsen; David A Katzenstein; Julio S G Montaner; Douglas D Richman; Michael S Saag; Mauro Schechter; Robert T Schooley; Melanie A Thompson; Stefano Vella; Paul A Volberding Journal: JAMA Date: 2002-07-10 Impact factor: 56.272
Authors: Debbie M Cheng; David Nunes; Howard Libman; John Vidaver; Julie K Alperen; Richard Saitz; Jeffrey H Samet Journal: Alcohol Clin Exp Res Date: 2007-03-31 Impact factor: 3.455
Authors: Marcel Zwahlen; Ross Harris; Margaret May; Robert Hogg; Dominique Costagliola; Frank de Wolf; John Gill; Gerd Fätkenheuer; Charlotte Lewden; Mike Saag; Sholmo Staszewski; Antonella d'Arminio Monforte; Jordi Casabona; Fiona Lampe; Amy Justice; Viktor von Wyl; Matthias Egger Journal: Int J Epidemiol Date: 2009-10-09 Impact factor: 7.196
Authors: Nicholas Petersdorf; Jennifer M Ross; Helen A Weiss; Ruanne V Barnabas; Judith N Wasserheit Journal: J Int AIDS Soc Date: 2016-09-19 Impact factor: 5.396
Authors: Beverly Allan; Kalysha Closson; Alexandra B Collins; Mia Kibel; Shenyi Pan; Zishan Cui; Taylor McLinden; Surita Parashar; Viviane Dias Lima; Jason Chia; Benita Yip; Rolando Barrios; Julio S G Montaner; Robert S Hogg Journal: BMJ Open Date: 2019-03-20 Impact factor: 2.692
Authors: Alicia C Thornton; Sophie Jose; Sanjay Bhagani; David Chadwick; David Dunn; Richard Gilson; Janice Main; Mark Nelson; Alison Rodger; Chris Taylor; Elaney Youssef; Clifford Leen; Mark Gompels; Stephen Kegg; Achim Schwenk; Caroline Sabin Journal: AIDS Date: 2017-11-28 Impact factor: 4.177